Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.21 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

24 25 Next >

3 Things You Need to Know if You Buy Iovance Biotherapeutics Today ↗

September 16, 2024

There's plenty of upside with this stock, but it might take a while to realize.

Via The Motley Fool

AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio? ↗

September 08, 2024

The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile.

Via Benzinga

Topics Artificial Intelligence

This Is the Biggest Risk With Iovance Biotherapeutics Stock ↗

September 06, 2024

Investors should brace for dilution.

Via The Motley Fool

Iovance Biotherapeutics to Present at Upcoming Conferences

September 03, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗

September 03, 2024

Via Benzinga

Looking Into Iovance Biotherapeutics's Recent Short Interest ↗

August 16, 2024

Via Benzinga

Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗

August 12, 2024

Via Benzinga

What the Options Market Tells Us About Iovance Biotherapeutics ↗

August 08, 2024

Via Benzinga

3 Monster Biotech Stocks to Buy Before 2025 ↗

September 02, 2024

These companies are nearly in the sweet spot of risk versus reward in biotech.

Via The Motley Fool

Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? ↗

August 27, 2024

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

August 16, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock ↗

August 14, 2024

It could demonstrate a few capabilities that no other biotech has as of yet.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

How Is The Market Feeling About Iovance Biotherapeutics? ↗

July 22, 2024

Via Benzinga

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗

August 09, 2024

Via Benzinga

Why Iovance Biotherapeutics Shares Are Soaring Today ↗

August 09, 2024

The biopharma company is proving its recently approved cancer therapy is marketable.

Via The Motley Fool

Why Is Iovance Bio (IOVA) Stock Up 18% Today? ↗

August 09, 2024

Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025.

Via InvestorPlace

Topics Earnings

Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges ↗

August 09, 2024

Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations.

Via Benzinga

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

August 09, 2024

Via Benzinga

IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

IOVA stock results show that Iovance Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

August 08, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

10 Best Small and Mid-Cap Stocks to Consider Buying in August ↗

August 01, 2024

A shift in market dynamics could favor these 10 growth stocks.

Via The Motley Fool

Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? ↗

July 31, 2024

Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.

Via The Motley Fool

Why Iovance Biotherapeutics Stock Stumbled Today ↗

July 29, 2024

One pundit warns of apparent manufacturing issues with the company's melanoma drug.

Via The Motley Fool

Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

July 29, 2024

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy ↗

July 29, 2024

Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led...

Via Benzinga

Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why. ↗

July 29, 2024

The Federal Reserve's fight against inflation may soon yield financial benefits.

Via The Motley Fool

Topics Economy

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 29, 2024

Via Benzinga

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗

July 28, 2024

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 23, 2024

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.